İNKAYA, A. Ç. Et Al. 2021. Pretreatment serum uric acid level is not a surrogate marker for the outcome of favipiravir treatment in COVID-19 patients. TURKISH JOURNAL OF MEDICAL SCIENCES , vol.51, no.5 , 2786-2788.

İNKAYA, A. Ç., KARA, E., ÇALIK BAŞARAN, N., ŞAHİN, T. K., UYAROĞLU, O. A., UZUN, Ö., ... ÜNAL, S.(2021). Pretreatment serum uric acid level is not a surrogate marker for the outcome of favipiravir treatment in COVID-19 patients. TURKISH JOURNAL OF MEDICAL SCIENCES , vol.51, no.5, 2786-2788.

İNKAYA, AHMET Et Al. "Pretreatment serum uric acid level is not a surrogate marker for the outcome of favipiravir treatment in COVID-19 patients," TURKISH JOURNAL OF MEDICAL SCIENCES , vol.51, no.5, 2786-2788, 2021

İNKAYA, AHMET Ç. Et Al. "Pretreatment serum uric acid level is not a surrogate marker for the outcome of favipiravir treatment in COVID-19 patients." TURKISH JOURNAL OF MEDICAL SCIENCES , vol.51, no.5, pp.2786-2788, 2021

İNKAYA, A. Ç. Et Al. (2021) . "Pretreatment serum uric acid level is not a surrogate marker for the outcome of favipiravir treatment in COVID-19 patients." TURKISH JOURNAL OF MEDICAL SCIENCES , vol.51, no.5, pp.2786-2788.

@article{article, author={AHMET ÇAĞKAN İNKAYA Et Al. }, title={Pretreatment serum uric acid level is not a surrogate marker for the outcome of favipiravir treatment in COVID-19 patients}, journal={TURKISH JOURNAL OF MEDICAL SCIENCES}, year=2021, pages={2786-2788} }